Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
24 July 2020Website:
http://www.nurixtx.comNext earnings report:
N/ALast dividends:
N/ANext dividends:
N/APrice
regular market | 3 min agoDividend
Analysts recommendations
Institutional Ownership
NRIX Latest News
Does Nurix Therapeutics, Inc. (NRIX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Nurix Therapeutics, Inc. (NRIX) came out with a quarterly loss of $0.71 per share versus the Zacks Consensus Estimate of a loss of $0.66. This compares to loss of $0.45 per share a year ago.
Nurix Therapeutics (NRIX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Expanded C-level team poised to accelerate development of NX-5948 in B cell malignancies Expanded C-level team poised to accelerate development of NX-5948 in B cell malignancies
Nurix Therapeutics (NRIX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Nurix (NRIX) is experiencing a rise in stock value due to positive early results showing clinical responses in the brain for its experimental targeted protein degrader, NX-5948. This drug is being developed to treat B cell malignancies.
Nurix Therapeutics, Inc. (NRIX) reported a quarterly loss of $0.76 per share, slightly better than the expected loss of $0.80 per share according to the Zacks Consensus Estimate. This is compared to a loss of $0.75 per share in the same quarter last year.
Nurix Therapeutics, Inc. (NRIX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Nurix Therapeutics, Inc. (NRIX) came out with a quarterly loss of $0.77 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to loss of $0.87 per share a year ago.
SAN FRANCISCO, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix, will present an overview of Nurix's achievements in 2023 and major goals for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024, at 3:00 p.m. PT.
- 1(current)
What type of business is Nurix Therapeutics?
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer. The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.
What sector is Nurix Therapeutics in?
Nurix Therapeutics is in the Healthcare sector
What industry is Nurix Therapeutics in?
Nurix Therapeutics is in the Biotechnology industry
What country is Nurix Therapeutics from?
Nurix Therapeutics is headquartered in United States
When did Nurix Therapeutics go public?
Nurix Therapeutics initial public offering (IPO) was on 24 July 2020
What is Nurix Therapeutics website?
https://www.nurixtx.com
Is Nurix Therapeutics in the S&P 500?
No, Nurix Therapeutics is not included in the S&P 500 index
Is Nurix Therapeutics in the NASDAQ 100?
No, Nurix Therapeutics is not included in the NASDAQ 100 index
Is Nurix Therapeutics in the Dow Jones?
No, Nurix Therapeutics is not included in the Dow Jones index
When was Nurix Therapeutics the previous earnings report?
No data
When does Nurix Therapeutics earnings report?
Next earnings report date is not announced yet